Organic & Biomolecular Chemistry

PAPER

Check for updates

Cite this: DOI: 10.1039/c7ob01778b

Regioselective oxidative cross-coupling of benzo [d]imidazo[2,1-b]thiazoles with styrenes: a novel route to C3-dicarbonylation[†]

Siddiq Pasha Shaik,^{a,b} Faria Sultana,^a A. Ravikumar,^c Satish Sunkari,^{a,b} Abdullah Alarifi^d and Ahmed Kamal * A^{a,b,c,d}

A novel I₂ promoted, highly efficient metal-free and peroxide-free greener domino protocol for the C3-dicarbonylation of benzo[d]imidazo[2,1-b]thiazoles (IBTs) with styrenes has been developed via oxidative cleavage of the $C(sp^2)$ -H bond, followed by C3-nucleophilic attack of IBT and oxidation. Interestingly, under these conditions 2-(benzo[d]imidazo[2,1-b]thiazol-2-yl)aniline gave the benzo[4',5']thiazolo [2',3':2,3]imidazo[4,5-c]quinoline derivative via oxidative cleavage of the $C(sp^2)$ -H bond, followed by Pictet-Spengler cyclization and aromatization. This method offers the advantages of broad substrate scope, ecofriendly feature and high atom economy apart from higher yields.

the

free

active heterocyclics.

Received 19th July 2017, Accepted 24th August 2017 DOI: 10.1039/c7ob01778b

rsc.li/obc

Introduction

The oxidative cross-coupling of two different C-H bonds for the construction of specific C-C bonds in the development of effective synthetic strategies to functionalize important pharmacophores is an ongoing interest in synthetic organic chemistry, medicinal chemistry and materials science.¹ Transition metals like Pd, Cu, Ag, Rh, and Ru play a major role in many oxidative cross-coupling reactions.² Recent literature reveals that nonmetallic molecular iodine also plays an important role in oxidative cross-coupling reactions.³ Molecular iodine mediated reactions are attractive and become alternatives to transition metals due to their lower toxicity, easy handling, ready availability, environmental benignity, the ability to operate under mild reaction conditions and lower costs.⁴ 1,2-Dicarbonyl compounds are valuable starting materials and important synthetic intermediates in the preparation of many fine chemicals that could be readily converted to many other functional groups, and as such have become attractive targets.⁵ Generally these are obtained by the oxidation of 1,2diols, alkenes and alkynes.⁶ Few successful and elegant pro-

dants and peroxides; thus there is need to develop methods that are free from oxidants and peroxides. Sulfur-containing heterocyclic compounds are frequently found in numerous natural products and occupy a privileged

cesses for the construction of C3-dicarbonyl indoles7 and

imidazo[1,2-a]pyridines⁸ have been reported. However, these

procedures are associated with some drawbacks, such as harsh

conditions, the use of expensive Pd catalysts and atom

economy issues. Recently, iodine mediated 1,2-dicarbonylation

indoles have been developed with methyl ketone in the presence of pyrrolidine⁹ and in its absence it gave the 2,2-bisindo-

lyl-1-arylethanones.¹⁰ This indicated that the pyrrolidine base

was essential for 1,2-dicarbonylation transformation. Later the

Atmakur group reported the same type of transformation with

imidazo[1,2-*a*]pyridines in the presence of acid.¹¹ In addition,

FeCl₃ catalyzed C3-dicarbonylation of imidazoheterocycles

with oxoaldehydes has been reported by the Hajra group.¹²

Although investigation in this field has been conducted,

with terminal alkenes via C(sp²)-H bond cleavage is still

challenging and highly desirable for 1,2-dicarbonyl

functionalization via C-H bond cleavage to obtain biologically

2-acylbenzothiazoles,^{14b} pyrazines,¹⁵ quinoxalines^{15,16} and

 α -ketoimides¹⁷ have been synthesized. However these pro-

cedures suffer from some disadvantages like, the use of oxi-

On the other hand widely employed domino reactions in modern organic synthesis have attracted researchers due to their high atom economy and less waste generation. Recently by using such a strategy isatins,¹³ 2-acyloxazoles,^{14a}

development of metal-free, peroxide-free, acid-base

and environmentally benign alternative methods

Published on 05 September 2017. Downloaded by Gazi Universitesi on 05/09/2017 13:57:53.



View Article Online

^aMedicinal Chemistry and Biotechnology Division, CSIR-Indian Institute of Chemical Technology (IICT), Hyderabad-500007, India. E-mail: ahmedkamal@iict.res.in ^bAcademy of Scientific and Innovative Research, New Delhi, 110025, India

^cDepartment of Medicinal Chemistry, National Institute of Pharmaceutical Education

[&]amp; Research (NIPER), Hyderabad 50037, India

^dCatalytic Chemistry Research Chair, Chemistry Department, College of Science, King Saud University, Riyadh 11451, Saudi Arabia

[†]Electronic supplementary information (ESI) available. See DOI: 10.1039/ c7ob01778b



Fig. 1 Biologically active benzo[d]imidazo[2,1-b]thiazole derivatives.

position in drug discovery as they exhibit interesting activities.¹⁸ Benzo[d]imidazo[2,1-b]-thiazole is one of the important fused tricyclic sulfur containing scaffolds (Fig. 1) as it exhibits diverse biological activities like antibacterial,¹⁹ antimicrobial,²⁰ antifungal,²¹ immunosuppressive,²² antiallergic,²³ nonsedative anxiolytic²⁴ (I with $IC_{50} = 60 \text{ nM}$) and antitumor²⁵ (III). Its other derivative AC220 (IV) is highly potent against FMS-like tyrosine kinase-3 (FLT3) and is in phase III clinical trials,²⁶ whereas another derivative (II) is employed for the PET imaging of brains of Alzheimer's patients as well as β-amyloid plaques.²⁷ The electron-rich nature of the C3 position in benzo [d]imidazo[2,1-b]-thiazole enables it to undergo direct C-H bond functionalization with electrophiles to form C-C bonds. Recently from this laboratory a potent cytotoxic agent (V) has been reported via the C3-arylation of benzo[d]imidazo[2,1-b]thiazole.²⁸ In addition to this, we developed a metal free oxidative cross-coupling of imidazoheterocycles with methylhetarenes.²⁹ In continuation of our interest regarding benzo[d]imidazo[2,1-b]-thiazole and their derivatives, herein we describe an iodine mediated highly desirable metal-free, peroxide-free and greener approach for the 1,2-dicarbonlation of benzo[d]imidazo[2,1-b]thiazole with commercially available styrenes using the greener oxidant O2 under mild conditions, and to the best of our knowledge, this protocol has not yet been reported.

Results and discussion

Initially, 2-phenylbenzo[d]imidazo[2,1-b]thiazole (1a) and styrene (2a) were chosen as model substrates in the presence of I₂ (1 equiv.) in DMSO at 100 °C under atmospheric conditions and the results are summarized in Table 1. To our delight, we obtained the desired oxidative cross-coupling product 3a in 62% yield, along with an *S*-methylated sideproduct 4 in 16% yield. Fortunately, the bisbenzo[d]imidazo [2,1-b]thiazole product like as in the case of indole with methyl ketone and styrene^{10,30} as well as the iodination product of 2-phenylimidazo [2,1-b]benzothiazole were not observed. The structure of the desired product 3a was confirmed by the characteristic carbonyl peaks appearing at δ 191.2 ppm
 Table 1
 Optimization conditions for the oxidative 1,2-dicarbonylation

 of 2-phenyl benzo[d]imidazo[2,1-b]thiazole with styrene^a



^{*a*} Reaction conditions: **1a** (1 mmol), **2a** (1.5 mmol), I₂, DMSO (2.0 mL) at the above mentioned conditions under open air. ^{*b*} Yield of the isolated product. ^{*c*} Dioxygen (1 atm) was used and the time was 8 h.

and δ 183.2 ppm (CDCl₃, 500 MHz) in ¹³C-NMR spectroscopy with a disappearance of the singlet at δ 7.89 ppm corresponding C3-H in the ¹H-NMR spectroscopy of 1a. Then, different types of iodide reagents such as N-iodosuccinimide (NIS), iodosobenzene diacetate (PhI(OAc)₂) and tetrabutylammonium iodide (TBAI) were screened; unfortunately the desired product was not obtained (Table 1, entries 2-4), thereby indicating that molecular I2 is essential for this conversion. Next we focused our attention towards optimizing the temperature; it is observed that the increase of temperature to 110 °C enhances the yield of both the desired product, as well as with S-methylated product. However further increase to 120 °C decreased the yield of the desired product and enhanced the S-methylated product. Moreover, when the amount of I2 was decreased to 0.2 equiv., there was a drastic decrease in the yield (Table 1, entry 7). The desired product was obtained in high yield with trace amounts of an S-methylated side-product upon enhancing the equivalent of I₂ to 1.6 mol%. It was also observed that by employing the combination of molecular I_2 (1.6 equiv.) with catalytic amount of acids (Table 1, entries 11 and 12), did not further improve the yields but led to the sole desired product. Finally we got the sole desired product in high yield (84%) when the molecular oxygen was applied as the oxidant. After obtaining the promising results we had changed solvents like toluene and DMF but these did not work (Table 1, entries 14 and 15), indicating that

DMSO played a crucial role in this reaction. Moreover, this method well tolerated the addition of water with the solvent and gave the desired product in good yield (Table 1, entry 16).

With the optimized conditions in hand, the generality and scope of this molecular iodine mediated C3-dicarbonylation of benzo[d]imidazo[2,1-b]thiazole was explored and the reactiondemonstrated wide substrate scope in terms of benzo[d]imidazo[2,1-b]thiazole and styrenes (Scheme 1). Benzo[d]imidazo[2,1-b]thiazoles having electron donating substituents like -Me and -OMe afforded the corresponding products in excellent yields (3a and 3b) and the chloro substitutent gave in good yield 3c without dehalogenation. To check the effect of the C-2 substituent the scope of this reaction was subsequently extended to the 2-arylbenzo[d]imidazo[2,1-b]thiazole derivatives. Phenyl ring bearing electron-donating groups (e.g., 4-Me, 4-OMe and 3,4-methelene dioxy) afforded the corresponding C3-dicarbonylation products in excellent yields (3d, 3e and 3i) and on the other hand electron withdrawing substituents like -F and -Cl produced the desired oxidative cross-coupling products smoothly in good yields (3f and 3g). However, phenyl ring bearing electron withdrawing groups such as 4-NO₂ prevented the reaction from proceeding due to decreased electron density in the imidazole ring of 2-phenylbenzo[d]imidazo[2,1-b]thiazole. Next to check the steric effects 2-bromophenyl linked to benzo[d]imidazo[2,1-b]thiazole was tested; it gave the corresponding product in moderate yield (3h). This indicated that



Scheme 1 Substrate scope of the present method. Reaction conditions: 1 (1 mmol), 2 (1.5 mmol) and I₂ (1.6 mmol) in DMSO (2.0 mL) at 110 °C under dioxygen (1 atm) for 8 h.

steric factors influenced reaction efficiency. In contrast to styrenes the electronic factors of a phenyl ring linked to benzo [d]imidazo[2,1-b]thiazole exhibit some influence on the efficiency of this reaction. Phenyl ring bearing electron-donating groups (e.g., 4-OMe) and halogenated groups (e.g., 4-Cl) gave the desired oxidative cross-coupling products smoothly in moderate to good yields (72-88%; 3ba-ha). In contrast to benzo[d]imidazo[2,1-b]thiazole, styrene bearing electron-donating groups (e.g., 4-OMe, 3,4-dimethoxy) as well as electronwithdrawing halogen groups (e.g., 4-F, 3-Cl) were smoothly converted to the corresponding products in good yields (3k-3n) under these optimized conditions. Thus the electronic factors of styrenes did not show any influence on the efficiency of the protocol. Furthermore, various substituted benzo[d]imidazo[2,1-b]thiazole and styrenes were also tested and gave the corresponding products in good to excellent yield (30-3x).

Next, the scope of the substrate was tested with imidazo [2,1-b]pyridine and imidazo[2,1-b]thiazole; they gave the corresponding products (**3y** and **3aa**) in good yield; however imidazo[1,2-a]pyrimidine gave the corresponding product (**3z**) in moderate yield (Scheme 2). It could be because of less electron density on the C3 position of imidazo[1,2-a]pyrimidine when compared to imidazo[2,1-b]pyridine and imidazo[2,1-b] thiazole; unfortunately the imidazo[1,5-a]pyridine derivative did not provide the desired product (**3ab**). Furthermore, when 2-(benzo[*a*]imidazo[2,1-b]thiazol-2-yl)aniline reacted with styrene under optimized conditions it gave the corresponding benzo [4',5']thiazolo[2',3':2,3]imidazo[4,5-c]quinoline (**3ac**) derivative in good yield *via* oxidative cleavage of the C(sp²)–H bond of styrene, followed by Pictet–Spengler cyclization and aromatization. Next we carried out a test with the heterocycle styrene (2-vinylpyridine)



Scheme 2 Scope of the imidazoheterocycles. Reaction conditions : 1 (1 mmol), 2a (1.5 mmol) and I₂ (1.6 mmol) in DMSO (2.0 mL) at 110 °C under dioxygen (1 atm) for 8 h. ^a 2a (1.5 mmol) and I₂ (1.6 mmol) in DMSO (2.0 mL) heated at 110 °C for 1 h under dioxygen (1 atm) and then adding 1a (1 mmol).

Paper

which gave the corresponding product (**3ad**) in less yield. It was also observed that 3-phenylimidazo[1,5-*a*]pyridine did not yield the corresponding coupled product, indicating that this protocol regioselectively takes place at the C3 position. To check the efficiency of aromatic benzaldehydes, 4-chlorobenz-aldehyde was examined with 6-phenylimidazo[2,1-*b*]pyridine under standard protocol conditions. However, we did not observe either the C3-carbonylated or the bisimidazo[2,1-*b*]pyridine product at all.

In order to propose the mechanistic pathway, some control experiments were carried out as shown in Scheme 3. In this context, styrene (2a) under the standard optimized conditions afforded phenylglyoxal (2ab) and the corresponding hydrated species in quantitative yield (Scheme 3a). The next condensation of 2-iodo-1-phenylethan-1-one (2aa) and phenylglyoxal (2ab) with 2-phenylbenzo[d]imidazo[2,1-b]thiazole (1a) under standard conditions gave the corresponding dicarbonylated product (3a) in excellent yield (Scheme 3b and c). Based on the control experiments (Scheme 3) and literature reports,^{9,11,29,31} a plausible mechanism is depicted in Scheme 4. Initially, styrene (2a) on reaction with I_2 in DMSO under molecular dioxygen converted into α -iodoketone (2aa) through consecutive iodination and oxidation. Subsequently it converted into phenylglyoxal (2ab) in DMSO by Kornblum oxidation. Then C3-nucleophilic addition of benzo[d]imidazo[2,1-b]thiazolewith phenylglyoxal, which was activated by iodine resulted the corresponding intermediate A, which on further oxidation gave the desired C3-dicarbonylated benzo[d]imidazo[2,1-b]thiazole product (3a). The S-methylated side-product 4 could be formed *via* the attack of 2-phenylbenzo[d]imidazo[2,1-b]thiazole (1a) with in situ generated DMS in the presence of molecular iodine; this gave the sulfonium intermediate. Then the sequential loss of MeI afforded the S-methylated product 4.32



Scheme 3 Control experiments.



Scheme 4 Possible reaction mechanism.

Conclusion

In conclusion, we have successfully established a novel, highly efficient molecular I_2 mediated metal-free, peroxide-free, acidbase free and greener domino approach for the site selective oxidative C3-dicarbonylation of IBTs with styrenes *via* oxidative cleavage of the $C(sp^2)$ –H bond, followed by the electron rich C3 attack of IBT and oxidation. This method proceeds under mild conditions with high regioselectivity and broad substrate scope under the greener oxidant molecular oxygen. Furthermore, using this simple method a library of C3-dicarbonylated imidazoheterocycle derivatives have been synthesized in good to excellent yields.

Experimental section

General information

All reagents and chemicals were purchased from commercial sources and used directly without further purification. The reaction courses and product mixtures were routinely checked by TLC which was done on a silica gel coated glass slide containing 60 GF-254, and visualized under UV irradiation and iodine. Column chromatography was performed using Merck 60-120 mesh silica gel. Proton (¹H) NMR spectra were recorded on Bruker UXNMR/XWIN-NMR (300 MHz) or Inova Varian-VXRunity (400, 500 MHz) instruments. Chemical shifts (δ) are reported in δ units, parts per million (ppm) downfield from an internal standard TMS and coupling constants (J) were expressed in hertz (Hz). Signal multiplicity patterns are designed as follows: s (singlet), d (doublet), t (triplet), quartet (q) ds (double singlet), dd (double doublet), m (multiplet) and br s (broad singlet). ESI spectra were recorded on a Micromass Quattro LC system using ESI+ software with a capillary voltage of 3.98 kV and an ESI mode positive ion trap detector. Highresolution mass spectra (HRMS) were recorded on a QSTAR XL hybrid MS-MS mass spectrometer. All the melting points were determined in an open glass capillary tube with an electrothermal melting point apparatus. All the substituted imidazoheterocycles were synthesized by previously reported methods.^{28,33–35} All the commercially available solvents were freshly distilled before use.

General experimental procedure for the synthesis of 3 (3a as an example)

To a solution of 2-phenylbenzo[*d*]imidazo[2,1-*b*]thiazole (1a, 1.0 equiv.) and styrene (2a, 1.5 equiv.) in DMSO (2.0 mL) I₂ (1.6 equiv.) was added and stirred at 110 °C for 8 h under molecular dioxygen atmosphere. TLC analysis indicated completion of the reaction. Upon completion, the mixture was diluted with ice cold water and extracted with EtOAc (3 × 20 mL). The extract was washed with 10% Na₂S₂O₃ solution (w/w), dried over anhydrous Na₂SO₄ and concentrated *in vacuo*. The residue was purified by column chromatography on silica gel (60–120 mesh) by using a petroleum ether and ethyl acetate solvent system (9:1) to afford the pure title compounds (3a).

1-Phenyl-2-(2-phenylbenzo[*d*]imidazo[2,1-*b*]thiazol-3-yl)ethane-1,2-dione (3a)

Light yellow solid; yield 84%; m. p. 181–183 °C (lit.¹² m. p. 179–180 °C); ¹H NMR (500 MHz, CDCl₃) δ 9.20 (d, J = 8.4 Hz, 1H), 7.78 (d, J = 8.39 Hz, 1H), 7.71 (dd, J = 7.1, 1.1 Hz, 2H), 7.55 (tt, J = 7.4, 1.5 Hz, 2H), 7.46 (t, J = 8.0 Hz, 1H), 7.37 (t, J = 7.9 Hz, 2H), 7.28 (dd, J = 8.2, 1.2 Hz, 2H), 7.22 (t, J = 7.6 Hz, 1H), 7.06 (t, J = 7.7 Hz, 2H); ¹³C NMR (125 MHz, CDCl₃) δ 191.2, 183.2, 160.3, 155.1, 134.0, 133.8, 133.4, 132.6, 130.1, 129.7, 129.4, 128.4, 127.7, 126.6, 125.8, 125.0, 123.5, 118.6; HRMS (ESI) (m/z) calcd for C₂₃H₁₅N₂O₂S [M + H]⁺ 383.0849; found 383.0874.

3-(Methylthio)-2-phenylbenzo[d]imidazo[2,1-b]thiazole (4)

Light yellow solid; m. p. 141–143 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.66 (d, J = 8.1 Hz, 1H), 8.17 (d, J = 7.3 Hz, 2H), 7.72 (d, J = 7.8 Hz, 1H), 7.50–7.344 (m, 3H), 7.38–7.34 (m, 2H), 2.39 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 150.8, 149.3, 133.7, 133.6, 130.2, 128.2, 127.8, 127.6, 126.2, 124.7, 124.0, 115.2, 114.0, 20.3; HRMS (ESI) (m/z) calcd for C₁₆H₁₃N₂S₂ [M + H]⁺ 297.0515; found 297.0529.

1-(7-Methoxy-2-phenylbenzo[*d*]imidazo[2,1-*b*]thiazol-3-yl)-2-phenylethane-1,2-dione (3b)

Light yellow solid; yield 86%; m. p. 119–121 °C (lit.¹² m. p. 119–120 °C); ¹H NMR (400 MHz, CDCl₃) δ 9.13 (d, J = 9.2 Hz, 1H), 7.71 (dd, J = 8.3, 1.2 Hz, 2H), 7.56 (tt, J = 7.4, 1.2 Hz, 1H), 7.37 (t, J = 7.7 Hz, 2H), 7.28–7.26 (m, 1H), 7.26–7.23 (m, 2H), 7.23–7.19 (m, 1H), 7.11 (dd, J = 9.2, 2.5 Hz, 1H), 7.05 (t, J = 7.8 Hz, 2H), 3.91 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 191.3, 183.2, 159.7, 157.7, 154.4, 134.0, 133.2, 132.7, 131.3, 130.1, 129.4, 129.3, 128.4, 128.1, 127.7, 124.8, 119.4, 113.9, 107.5, 55.8; HRMS (ESI) (m/z) calcd for C₂₄H₁₇N₂O₃S [M + H]⁺ 413.0954; found 413.0964.

1-(7-Chloro-2-phenylbenzo[*d*]imidazo[2,1-*b*]thiazol-3-yl)-2-phenylethane-1,2-dione (3c)

Light yellow solid; yield 79%; m. p. 142–144 °C (lit.¹² m. p. 144–145 °C); ¹H NMR (500 MHz, CDCl₃) δ 9.18 (d, J = 9.0 Hz, 1H), 7.76 (d, J = 2.1 Hz, 1H), 7.71 (dd, J = 8.3, 1.3 Hz, 2H), 7.57 (td, J = 7.4, 1.0 Hz, 1H), 7.53 (dd, J = 9.0, 1.9 Hz, 1H), 7.38 (t, J = 7.9 Hz, 2H), 7.27 (s, 1H), 7.26 (s, 1H), 7.23 (t, J = 7.4 Hz, 1H), 7.05 (t, J = 7.6 Hz, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 191.1, 183.4, 160.4, 154.9, 134.1, 133.0, 132.5, 132.4, 131.6, 131.3, 130.1, 129.5, 129.4, 128.4, 127.9, 127.1, 125.1, 123.2, 119.6; HRMS (ESI) (m/z) calcd for C₂₃H₁₄ClN₂O₂S [M + H]⁺ 417.0459; found 417.0464.

1-Phenyl-2-(2-(*p*-tolyl)benzo[*d*]imidazo[2,1-*b*]thiazol-3-yl) ethane-1,2-dione (3d)

Light yellow solid; yield 81%; m. p. 99–101 °C (lit.¹² m. p. 95–96 °C); ¹H NMR (500 MHz, CDCl₃) δ 9.20 (d, J = 8.3 Hz, 1H), 7.76 (d, J = 8.3 Hz, 1H), 7.1 (d, J = 8.2 Hz, 2H), 7.58–7.54 (m, 2H), 7.46 (t, J = 7.3 Hz, 1H), 7.38 (t, J = 7.6 Hz, 2H), 7.16 (d, J = 7.9 Hz, 2H), 6.85 (d, J = 7.7 Hz, 2H), 2.24 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 191.4, 183.2, 160.6, 152.2, 139.5, 133.9, 133.2, 130.0, 129.7, 129.7, 129.4, 128.5, 128.2, 126.6, 125.7, 125.0, 123.6, 118.6, 21.2; HRMS (ESI) (m/z) calcd for C₂₄H₁₇N₂O₂S [M + H]⁺ 397.1005; found 397.1010.

1-(2-(4-Methoxyphenyl)benzo[*d*]imidazo[2,1-*b*]thiazol-3-yl)-2phenylethane-1,2-dione (3e)

Light yellow solid; yield 88%; m. p. 104–106 °C (lit.¹² m. p. 96–97 °C); ¹H NMR (500 MHz, CDCl₃) δ 9.19 (d, J = 8.4 Hz, 1H), 7.78 (d, J = 7.9 Hz, 1H), 7.73 (dd, J = 8.3, 1.2 Hz, 2H), 7.56 (t, J = 7.4 Hz, 2H), 7.46 (t, J = 7.3 Hz, 1H), 7.38 (t, J = 7.9 Hz, 2H), 7.19 (d, J = 8.6, 2H), 6.57 (d, J = 8.6, 2H), 3.72 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 191.5, 183.3, 160.6, 155.3, 134.0, 133.2, 131.6, 129.8, 129.4, 128.4, 126.7, 125.8, 125.0, 123.6, 118.7, 113.3, 55.2; HRMS (ESI) (m/z) calcd for C₂₄H₁₇N₂O₃S [M + H]⁺ 413.0954; found 413.0970.

1-(2-(4-Fluorophenyl)benzo[*d*]imidazo[2,1-*b*]thiazol-3-yl)-2phenylethane-1,2-dione (3f)

Light yellow solid; yield 72%; m. p. 140–142 °C (lit.¹² m. p. 139–140 °C); ¹H NMR (500 MHz, CDCl₃) δ 9.21 (d, J = 8.3 Hz, 1H), 7.80 (d, J = 8.0 Hz, 1H), 7.71 (d, J = 8.0 Hz, 2H), 7.55 (t, J = 7.4 Hz, 2H), 7.49 (t, J = 7.6 Hz, 1H), 7.40 (t, J = 7.6 Hz, 2H), 7.25–7.22 (m, 2H), 6.65 (t, J = 8.5 Hz, 2H); ¹³C NMR (125 MHz, CDCl₃) δ 191.5, 183.1, 163.4 (J_{C-F} = 249 Hz), 159.2, 155.3, 134.3, 133.9, 133.0, 132.1 (J_{C-F} = 9 Hz), 129.8, 129.4, 128.7, 128.5, 126.8, 126.0, 125.2, 123.6, 118.7, 114.8 (J_{C-F} = 21 Hz); HRMS (ESI) (m/z) calcd for C₂₃H₁₄FN₂O₂S [M + H]⁺ 401.0755; found 401.0762.

1-(2-(4-Chlorophenyl)benzo[*d*]imidazo[2,1-*b*]thiazol-3-yl)-2-phenylethane-1,2-dione (3g)

Yellow solid; yield 77%; m. p. 167–169 °C (lit.¹² m. p. 166–168 °C); ¹H NMR (400 MHz, CDCl₃) δ 9.20 (d, J = 8.4 Hz, 1H), 7.78 (dd, J = 8.0, 1.1 Hz, 1H), 7.71 (dd, J = 8.4,

Organic & Biomolecular Chemistry

1.3 Hz, 2H), 7.62–7.56 (m, 2H), 7.49 (td, J = 8.0, 1.2 Hz, 1H), 7.41 (t, J = 7.9 Hz, 2H), 7.18 (d, J = 8.4 Hz, 2H), 7.03 (d, J = 8.4 Hz, 2H); ¹³C NMR (125 MHz, CDCl₃) δ 191.5, 183.0, 158.9, 155.3, 135.7, 134.3, 133.9, 133.0, 131.5, 131.0, 129.8, 129.4, 128.5, 128.0, 126.8, 126.0, 125.2, 123.7, 118.7; HRMS (ESI) (m/z) calcd for C₂₃H₁₄ClN₂O₂S [M + H]⁺ 417.0459; found 417.0462.

1-(2-(2-Bromophenyl)benzo[*d*]imidazo[2,1-*b*]thiazol-3-yl)-2-phenylethane-1,2-dione (3h)

Yellow solid; yield 53%; m. p. 199–201 °C; ¹H NMR (500 MHz, CDCl₃) δ 9.23 (d, J = 8.3 Hz, 1H), 7.81 (d, J = 7.7 Hz, 1H), 7.62–7.58 (m, 3H), 7.55–7.48 (m, 2H), 7.33 (t, J = 7.7 Hz, 2H), 7.24–7.18 (m, 2H), 7.07–7.02 (m, 2H); ¹³C NMR (125 MHz, CDCl₃) δ 191.7, 182.9, 158.2, 155.1, 134.3, 133.8, 133.2, 133.0, 132.2, 132.1, 130.8, 130.0, 129.3, 128.3, 126.8, 126.2, 126.1, 125.9, 124.7, 123.7, 118.8; ¹³C NMR (125 MHz, CDCl₃) δ 191.7, 182.9, 158.2, 133.0, 132.2, 133.0, 132.2, 132.1, 130.8, 130.0, 129.3, 128.3, 126.8, 126.2, 126.1, 125.9, 124.7, 123.7, 118.8; 126.8, 126.2, 126.1, 125.9, 124.7, 123.7, 118.8; HRMS (ESI) (m/z) calcd for C₂₃H₁₃BrN₂O₂S [M + H]⁺ 459.9881; found 460.9976.

1-(2-(Benzo[*d*][1,3]dioxol-5-yl)benzo[*d*]imidazo[2,1-*b*]thiazol-3-yl)-2-phenylethane-1,2-dione (3i)

Light yellow solid; yield 81%; m. p. 197–199 °C; ¹H NMR (500 MHz, CDCl₃) δ 9.19 (d, J = 8.3 Hz, 1H), 7.79–7.76 (m, 3H), 7.61–7.54 (m, 2H), 7.50–7.41 (m, 3H), 6.79 (s, 1H), 6.69 (dd, J = 7.9, 1.5 Hz, 1H), 6.39 (d, J = 7.9 Hz, 1H), 5.88 (s, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 191.2, 182.9, 159.5, 155.0, 148.3, 146.7, 134.4, 133.3, 132.5, 129.4, 129.1, 126.0, 124.9, 124.9, 124.5, 117.6, 109.7, 107.2, 101.2; HRMS (ESI) (m/z) calcd for C₂₄H₁₅N₂O₄S [M + H]⁺ 427.0747; found 427.0764.

1-(4-Methoxyphenyl)-2-(2-phenylbenzo[*d*]imidazo[2,1-*b*]thiazol-3-yl)ethane-1,2-dione (3k)

Light yellow solid; yield 79%; m. p. 151–153 °C; ¹H NMR (500 MHz, CDCl₃) δ 9.18 (d, J = 8.5 Hz, 1H), 7.74 (d, J = 7.9 Hz, 1H), 7.70 (d, J = 8.8 Hz, 2H), 7.54 (t, J = 7.7 Hz, 1H), 7.45 (t, J = 7.6 Hz, 1H), 7.30 (d, J = 7.2 Hz, 2H), 7.23 (t, J = 7.4 Hz, 1H), 7.10 (t, J = 7.6 Hz, 2H), 6.86 (d, J = 8.8 Hz, 2H), 3.87 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 189.9, 183.5, 164.2, 160.1, 154.9, 133.9, 132.7, 131.8, 130.0, 129.8, 129.3, 127.6, 126.6, 126.4, 125.7, 125.1, 123.5, 118.6, 113.7, 55.4; HRMS (ESI) (m/z) calcd for C₂₄H₁₇N₂O₃S [M + H]⁺ 413.0954; found 413.0960.

1-(3,4-Dimethoxyphenyl)-2-(2-phenylbenzo[*d*]imidazo[2,1-*b*] thiazol-3-yl)ethane-1,2-dione (3l)

Light yellow solid; yield 76%; m. p. 173–175 °C; ¹H NMR (500 MHz, CDCl₃) δ 9.20 (d, J = 8.3 Hz, 1H), 7.78 (dd, J = 8.0, 0.8 Hz, 1H), 7.56 (td, J = 7.3, 1.2 Hz, 1H), 7.48–7.44 (m, 2H), 7.29 (dd, J = 6.8, 1.2 Hz, 2H), 7.23 (t, J = 7.4 Hz, 1H), 7.11–7.08 (m, 3H), 6.83 (d, J = 8.5 Hz, 1H), 3.96 (s, 3H), 3.83 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 190.2, 183.3, 160.1, 154.9, 148.9, 133.9, 132.8, 130.0, 129.8, 129.1, 127.7, 126.6, 125.8, 125.4, 125.2, 123.5, 118.6, 110.2, 109.8, 56.0, 55.8; HRMS (ESI) (m/z) calcd for C₂₅H₁₉N₂O₄S [M + H]⁺ 443.1060; found 443.1068.

1-(4-Fluorophenyl)-2-(2-phenylbenzo[*d*]imidazo[2,1-*b*]thiazol-3-yl)ethane-1,2-dione (3m)

Yellow solid; yield 81%; m. p. 201–203 °C; ¹H NMR (500 MHz, CDCl₃) δ 9.17 (d, J = 7.2 Hz, 1H), 7.78–7.74 (m, 3H), 7.56 (s, 1H), 7.47 (s, 1H), 7.27–7.24 (m, 3H), 7.10–7.05 (m, 4H); ¹³C NMR (125 MHz, CDCl₃) δ 189.7, 182.8, 166.1(J_{C-F} = 257 Hz), 160.4, 155.3, 133.8, 13 2.6, 132.1 (J_{C-F} = 9 Hz), 130.1, 129.8 (J_{C-F} = 15 Hz), 129.5, 127.8, 126.7, 125.9, 125., 123.6, 118.5, 115.6 (J_{C-F} = 21 Hz); HRMS (ESI) (m/z) calcd for C₂₃H₁₄FN₂O₂S [M + H]⁺ 401.0755; found 401.0760.

1-(3-Chlorophenyl)-2-(2-phenylbenzo[*d*]imidazo[2,1-*b*]thiazol-3-yl)ethane-1,2-dione (3n)

Light yellow solid; yield 76%; m. p. 183–185 °C; ¹H NMR (500 MHz, CDCl₃) δ 9.19 (d, J = 8.5 Hz, 1H), 7.80 (d, J = 8.0 Hz, 1H), 7.61–7.56 (m, 3H), 7.53–7.47 (m, 2H), 7.32 (t, J = 7.7 Hz, 1H), 7.30–7.22 (m, 4H), 7.10 (t, J = 7.6 Hz, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 190.1, 182.4, 160.7, 155.5, 134.8, 134.7, 133.9, 132.5, 130.2, 129.8, 129.7, 129.6, 129.0, 127.9, 127.5, 126.8, 126.0, 124.9, 123.7, 118.6; HRMS (ESI) (m/z) calcd for C₂₃H₁₄ClN₂O₂S [M + H]⁺ 417.0459; found 417.0461.

1-(4-Methoxyphenyl)-2-(2-(4-methoxyphenyl)benzo[*d*]imidazo [2,1-*b*]thiazol-3-yl)ethane-1,2-dione (30)

Yellow solid; yield 81%; m. p. 187–189 °C; ¹H NMR (500 MHz, CDCl₃) δ 9.19 (d, J = 8.4 Hz, 1H), 7.77 (d, J = 7.8 Hz, 1H), 7.71 (d, J = 8.8 Hz, 2H), 7.55 (t, J = 7.47 Hz, 1H), 7.46 (t, J = 7.3 Hz, 1H), 7.26 (d, J = 8.68 Hz, 2H), 6.86 (d, J = 9.0 Hz, 2H), 6.56 (d, J = 8.7 Hz, 2H), 3.88 (s, 3H), 3.74 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 190.2, 183.6, 164.2, 160.5, 160.2, 155.0, 134.0, 131.8, 131.5, 129.7, 126.6, 126.5, 125.7, 125.2, 125.1, 123.6, 118.6, 113.7, 113.2, 55.5, 55.2; HRMS (ESI) (m/z) calcd for C₂₅H₁₉N₂O₄S [M + H]⁺ 443.1060; found 443.1067.

1-(3,4-Dimethoxyphenyl)-2-(2-(4-methoxyphenyl)benzo[*d*] imidazo[2,1-*b*]thiazol-3-yl)ethane-1,2-dione (3p)

Yellow solid; yield 79%; m. p. 143–145 °C; ¹H NMR (400 MHz, CDCl₃) δ 9.20 (d, J = 8.4 Hz, 1H), 7.77 (d, J = 7.9 Hz, 1H), 7.55 (t, J = 7.9 Hz, 1H), 7.47–7.42 (m, 2H), 7.18 (d, J = 8.5 Hz, 2H), 7.10 (s, 1H), 6.81 (d, J = 8.4 Hz, 1H), 6.61 (d, J = 8.5 Hz, 2H), 3.95 (s, 3H), 3.83 (s, 3H), 3.72 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 190.6, 183.4, 160.4, 160.3, 154.1, 149.0, 134.0, 131.6, 129.7, 126.8, 126.7, 125.7, 125.3, 125.2, 123.6, 118.7, 113.1, 110.1, 109.8, 56.1, 55.8, 55.1; HRMS (ESI) (m/z) calcd for C₂₆H₂₁N₂O₅S [M + H]⁺ 473.1166; found 473.1171.

1-(4-Fluorophenyl)-2-(2-(4-methoxyphenyl)benzo[*d*]imidazo [2,1-*b*]thiazol-3-yl)ethane-1,2-dione (3q)

Light brown solid; yield 85%; m. p. 173–175 °C; ¹H NMR (400 MHz, CDCl₃) δ 9.17 (d, J = 8.0 Hz, 1H), 7.78–7.73 (m, 3H), 7.56 (td, J = 7.4, 1.2 Hz, 1H), 7.46 (td, J = 7.0, 1.1 Hz, 1H), 7.20 (d, J = 7.6, 2H), 7.06 (t, J = 8.5, 2H), 6.61 (d, J = 8.6, 2H), 3.73 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 189.9, 182.8, 166.1 (J_{C-F} = 257 Hz), 160.6, 160.5, 155.4, 133.9, 132.1 (J_{C-F} = 10 Hz), 131.6, 129.7, 126.7, 125.8, 125.0, 124.9, 123.6, 118.5, 115.7 (J_{C-F} = 22 Hz),

113.3, 55.2; HRMS (ESI) (m/z) calcd for $C_{24}H_{16}FN_2O_3S [M + H]^+$ 431.0860; found 431.0866.

1-(3-Chlorophenyl)-2-(2-(4-methoxyphenyl)benzo[*d*]imidazo [2,1-*b*]thiazol-3-yl)ethane-1,2-dione (3r)

Light yellow solid; yield 79%; m. p. 165–167 °C; ¹H NMR (400 MHz, CDCl₃) δ 9.18 (d, J = 8.4 Hz, 1H), 7.77 (d, J = 8.0 Hz, 1H), 7.62–7.45 (m, 5H), 7.32 (t, J = 7.8 Hz, 1H), 7.17 (d, J = 8.8 Hz, 2H), 6.62 (d, J = 8.6 Hz, 2H), 3.76 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 190.5, 182.6, 161.0, 155.7, 135.0, 134.9, 134.1, 134.0, 131.8, 129.9, 129.8, 129.0, 127.6, 126.9, 126.0, 125.1, 125.0, 123.8, 118.8, 113.5, 55.4; HRMS (ESI) (m/z) calcd for C₂₄H₁₆ClN₂O₃S [M + H]⁺ 447.0565; found 447.0568.

1-(2-(4-Chlorophenyl)benzo[*d*]imidazo[2,1-*b*]thiazol-3-yl)-2-(4-methoxyphenyl)ethane-1,2-dione (3s)

Light yellow solid; yield 73%; m. p. 197–199 °C; ¹H NMR (400 MHz, CDCl₃) δ 9.16 (d, J = 8.4 Hz, 1H), 7.79 (dd, J = 7.9, 0.9 Hz, 1H), 7.69 (d, J = 8.9, 2H), 7.57 (td, J = 8.5, 1.2 Hz, 1H), 7.47 (td, J = 7.0, 0.9 Hz, 1H), 7.21 (d, J = 8.4 Hz, 2H), 7.05 (d, J = 8.4 Hz, 2H), 6.87 (d, J = 8.9 Hz, 2H), 3.90 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 190.1, 183.4, 164.5, 158.6, 155.1, 135.6, 133.9, 131.8, 131.4, 131.2, 129.8, 127.9, 126.7, 126.2, 125.9, 125.3, 123.6, 118.7, 113.9, 55.6; HRMS (ESI) (m/z) calcd for C₂₄H₁₅ClN₂NaO₃S [M + Na]⁺ 469.0384; found 469.0391.

1-(2-(4-Chlorophenyl)benzo[*d*]imidazo[2,1-*b*]thiazol-3-yl)-2-(3,4-dimethoxyphenyl)ethane-1,2-dione (3t)

Light yellow solid; yield 75%; m. p. 169–171 °C; ¹H NMR (400 MHz, CDCl₃) δ 9.21 (d, J = 8.4 Hz, 1H), 7.8 (dd, J = 8.0, 0.8 Hz, 1H), 7.58 (td, J = 8.5, 1.2 Hz, 1H), 7.48 (td, J = 7.0, 1.1 Hz, 1H), 7.44 (dd, J = 8.3, 1.9 Hz, 1H), 7.20 (d, J = 8.4 Hz, 2H), 7.08–7.03 (m, 3H), 6.84 (d, J = 8.4 Hz, 1H), 3.97 (s, 3H), 3.87 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 190.4, 183.1, 158.7, 155.1, 154.5, 149.2, 135.5, 133.9, 131.4, 131.3, 129.8, 129.1, 127.9, 126.8, 126.5, 126.0, 125.4, 123.6, 118.7, 109.9, 109.9, 56.1, 55.9; HRMS (ESI) (m/z) calcd for C₂₅H₁₈ClN₂O₄S [M + H]⁺ 477.0670; found 477.0674.

1-(2-(4-Chlorophenyl)benzo[*d*]imidazo[2,1-*b*]thiazol-3-yl)-2-(4-fluorophenyl)ethane-1,2-dione (3u)

Yellow solid; yield 81%; m. p. 175–177 °C; ¹H NMR (400 MHz, CDCl₃) δ 9.17 (d, J = 8.3 Hz, 1H), 7.79 (d, J = 7.9 Hz, 1H), 7.76–7.73 (m, 2H), 7.58 (t, J = 8.4 Hz, 1H), 7.49 (t, J = 8.1 Hz, 1H), 7.18 (d, J = 8.4 Hz, 2H), 7.14–7.01 (m, 4H); ¹³C NMR (125 MHz, CDCl₃) δ 189.9, 182.6, 166.3 (J_{C-F} = 258 Hz), 165.3, 159.0, 155.4, 135.9, 133.8, 132.1 (J_{C-F} = 10 Hz), 131.5, 131.1, 129.8, 129.5, 128.0, 126.8, 126.1, 123.7, 118.7, 115.9 (J_{C-F} = 21 Hz); HRMS (ESI) (m/z) calcd for C₂₃H₁₃ClFN₂O₂S [M + H]⁺ 435.0365; found 435.0336.

1-(2-(4-Chlorophenyl)-7-methoxybenzo[*d*]imidazo[2,1-*b*]thiazol-3-yl)-2-phenylethane-1,2-dione (3v)

Yellow solid; yield 76%; m. p. 175–177 °C; ¹H NMR (300 MHz, CDCl₃ + DMSO-d₆) δ 9.10 (d, *J* = 9.2 Hz, 1H), 7.69 (d, *J* = 7.7 Hz, 2H), 7.61 (s, 1H), 7.43 (t, *J* = 7.4 Hz, 2H), 7.38 (d, *J* = 2.2 Hz,

1H), 7.18–7.10 (m, 3H), 7.03 (d, J = 8.3 Hz, 2H), 3.93 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 190.3, 182.2, 158.5, 157.9, 154.8, 135.9, 135.0, 134.6, 134.1, 131.5, 131.1, 129.8, 129.1, 128.1, 127.3, 124.8, 119.5, 114.1, 107.6, 55.9; HRMS (ESI) (m/z) calcd for C₂₄H₁₆ClN₂O₃S [M + H]⁺ 447.0565; found 447.0571.

1-(3-Chlorophenyl)-2-(2-(4-chlorophenyl)-7-methoxybenzo[*d*] imidazo[2,1-*b*]thiazol-3-yl)ethane-1,2-dione (3w)

Light yellow solid; yield 71%; m. p. 171–173 °C; ¹H NMR (500 MHz, CDCl₃) δ 9.10 (d, J = 9.1 Hz, 1H), 7.69 (d, J = 7.4 Hz, 2H), 7.59 (t, J = 7.4 Hz, 1H), 7.40 (t, J = 7.6 Hz, 2H), 7.18 (d, J = 8.2 Hz, 2H), 7.10 (dd, J = 9.3, 2.4 Hz, 1H), 7.02 (d, J = 8.2 Hz, 2H), 3.92 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 191.6, 183.0, 158.2, 157.8, 154.5, 135.6, 134.3, 133.0, 131.5, 131.3, 131.1, 129.4, 128.5, 128.0, 125.0, 119.6, 114.0, 107.6, 55.8; HRMS (ESI) (m/z) calcd for C₂₄H₁₅Cl₂N₂O₃S [M + H]⁺ 481.0175; found 481.0174.

1-(3,4-Dimethoxyphenyl)-2-(7-methoxy-2-phenylbenzo[*d*] imidazo[2,1-*b*]thiazol-3-yl)ethane-1,2-dione (3x)

Light yellow solid; yield 74%; m. p. 213–215 °C; ¹H NMR (300 MHz, CDCl₃ + DMSO-d₆) δ 9.10 (d, J = 9.2 Hz, 1H), 7.54–7.51 (m, 1H), 7.44 (dd, J = 8.4, 1.8 Hz, 1H), 7.34 (s, 1H), 7.24 (d, J = 5.0 Hz, 2H), 7.14–7.04 (m, 4H), 6.88 (d, J = 8.49 Hz, 1H), 3.97 (s, 3H), 3.93 (s, 3H), 3.82 (s, 3H); ¹³C NMR (75 MHz, CDCl₃ + DMSO-d₆) δ 190.0, 183.1, 158.7, 157.2, 154.1, 148.5, 132.6, 131.1, 129.9, 129.0, 127.4, 125.7, 125.4, 124.4, 118.5, 114.1, 110.6, 110.0, 108.5, 55.8, 55.7, 55.4; HRMS (ESI) (m/z) calcd for C₂₆H₂₁N₂O₅S [M + H]⁺ 473.1165; found 473.1162.

1-Phenyl-2-(2-phenylimidazo[1,2-*a*]pyridin-3-yl)ethane-1,2dione (3y)

Yellow solid; yield 81%; m. p. 121–123 °C (lit.¹² m. p. 121–122 °C); ¹H NMR (500 MHz, CDCl₃) δ 9.83 (d, J = 6.8 Hz, 1H), 7.86 (d, J = 9.0 Hz, 1H), 7.72 (dd, J = 8.3, 1.2 Hz, 2H), 7.68–7.65 (m, 1H), 7.56 (t, J = 8.5 Hz, 1H), 7.38 (t, J = 7.6 Hz, 1H), 7.30 (dd, J = 8.2, 1.3 Hz, 2H), 7.26–7.22 (m, 2H), 7.09 (t, J = 7.7 Hz, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 191.2, 184.4, 158.5, 148.2, 134.0, 133.3, 132.8, 130.9, 129.9, 129.4, 129.3, 129.2, 128.4, 127.8, 118.8, 117.5, 115.7; HRMS (ESI) (m/z) calcd for C₂₁H₁₅N₂O₂ [M + H]⁺ 327.1128; found 327.1138.

1-Phenyl-2-(2-(*p*-tolyl)imidazo[1,2-*a*]pyrimidin-3-yl)ethane-1,2dione (3z)

White solid; yield 67%; m. p. 164–166 °C (lit.¹² m. p. 165–167 °C); ¹H NMR (500 MHz, CDCl₃) δ 10.03 (d, J = 6.8 Hz, 1H), 8.89 (s, 1H), 7.76 (d, J = 7.4 Hz, 2H), 7.61 (t, J = 7.3 Hz, 2H), 7.42 (t, J = 7.6 Hz, 3H), 7.24 (s, 1H), 6.92 (d, J = 7.6 Hz, 2H), 2.28 (s, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 190.7, 185.2, 159.9, 154.7, 150.7, 140.2, 136.8, 134.3, 130.0, 130.0, 129.5, 129.2, 128.7, 128.6, 117.0, 111.6, 21.3; HRMS (ESI) (m/z) calcd for C₂₁H₁₆N₃O₂ [M + H]⁺ 342.1237; found 342.1265.

1-(6-(4-Fluorophenyl)imidazo[2,1-*b*]thiazol-5-yl)-2-phenylethane-1,2-dione (3aa)

Yellow solid; yield 78%; m. p. 153–155 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.56 (d, J = 4.4 Hz, 1H), 7.75 (dd, J = 8.4, 1.3 Hz, 2H), 7.60 (t, J = 7.4 Hz, 1H), 7.43 (t, J = 7.8 Hz, 2H), 7.30–7.26 (m, 2H), 7.15 (d, J = 4.4 Hz, 1H), 6.81 (t, J = 8.6 Hz, 2H); ¹³C NMR (125 MHz, CDCl₃) δ 191.7, 182.8, 163.3 (J_{C-F} = 250 Hz), 157.3, 156.0, 134.5, 133.0, 131.6 (J_{C-F} = 8 Hz), 129.4, 128.7, 121.9, 115.0 (J_{C-F} = 22 Hz), 115.0; HRMS (ESI) (m/z) calcd for $C_{19}H_{12}FN_2O_2S$ [M + H]⁺ 351.0598; found 351.0603.

Benzo[4',5']thiazolo[2',3':2,3]imidazo[4,5-*c*]quinolin-6-yl (phenyl)methanone (3ac)

Yellow solid; yield 63%; m. p. 238–240 °C; ¹H NMR (500 MHz, CDCl₃) δ 8.74–8.70 (m, 1H), 8.31–8.21 (m, 2H), 8.27–8.23 (m, 1H), 7.80–7.50 (m, 3H), 7.72 (t, *J* = 7.4 Hz, 1H), 7.59 (t, *J* = 7.6 Hz, 2H), 7.54–7.51 (m, 1H), 7.41–7.36 (m, 2H); ¹³C NMR (125 MHz, CDCl₃) δ 194.2, 158.3, 151.4, 143.0, 137.5, 135.6, 134.4, 133.2, 131.5, 129.7, 129.0, 128.7, 128.0, 126.7, 125.0, 124.1, 122.2, 122.0, 116.1; HRMS (ESI) (*m*/*z*) calcd for C₂₃H₁₄N₃OS [M + H]⁺ 380.0852; found 380.0867.

1-(7-Chloro-2-phenylbenzo[*d*]imidazo[2,1-*b*]thiazol-3-yl)-2-(pyridin-2-yl)ethane-1,2-dione (3ad)

Yellow solid; yield 51%; m. p. 203–205 °C; ¹H NMR (500 MHz, CDCl₃) δ 9.29 (d, J = 9.0 Hz, 1H), 8.63 (d, J = 4.4 Hz, 1H), 7.76 (d, J = 1.9 Hz, 1H), 7.70 (td, J = 7.7, 1.3 Hz, 1H), 7.57 (d, J = 7.7 Hz, 1H), 7.51 (dd, J = 9.0, 1.9 Hz, 1H), 7.44–7.41 (m, 1H), 7.28 (d, J = 7.0 Hz, 2H), 7.20 (t, J = 7.4 Hz, 1H), 7.02 (t, J = 7.6 Hz, 2H); ¹³C NMR (125 MHz, CDCl₃) δ 191.2, 184.3, 160.3, 154.8, 151.4, 149.1, 136.8, 132.7, 132.5, 131.6, 131.2, 130.4, 129.5, 127.7, 127.5, 127.1, 125.3, 123.1, 123.0, 120.1; HRMS (ESI) (m/z) calcd for C₂₂H₂₃N₃O₂ClS [M + H]⁺ 418.0411; found 418.0417.

Conflicts of interest

There are no conflicts of interest to declare.

Acknowledgements

The authors thank CSIR, UGC and NIPER-H, for the award of fellowships. We also acknowledge funding received from the project entitled 'Affordable Cancer Therapeutics (ACT)' under the XIIth Five Year plan and the International Scientific Partnership Program ISPP at King Saud University for funding this research work through ISPP#0054.

References

1 (a) C. Liu, H. Zhang, W. Shi and A. W. Lei, *Chem. Rev.*, 2011, **111**, 1780; (b) W. Shi, C. Liu and A. W. Lei, *Chem. Soc. Rev.*, 2011, **40**, 2761; (c) Z. Z. Shi, C. Zhang, C. H. Tang and

N. Jiao, *Chem. Soc. Rev.*, 2012, **41**, 3381; (*d*) C. Zhang, C. H. Tang and N. Jiao, *Chem. Soc. Rev.*, 2012, **41**, 3464; (*e*) B. J. Li and Z. J. Shi, *Chem. Soc. Rev.*, 2012, **41**, 5588; (*f*) T. L. Chan, Y. Wu, P. Y. Choy and F. Y. Kwong, *Chem.* – *Eur. J.*, 2013, **19**, 15802; (*g*) J. Xie, C. D. Pan, A. Abdukadera and C. J. Zhu, *Chem. Soc. Rev.*, 2014, **43**, 5245; (*h*) C. L. Sun and Z. J. Shi, *Chem. Rev.*, 2014, **114**, 9219.

- 2 (a) P. S. Wang, H. C. Lin, Y. J. Zhai, Z. Y. Han and L. Z. Gong, Angew. Chem., Int. Ed., 2014, 53, 12218; (b) T. Tomakinian, R. Guillot, C. Kouklovsky and G. Vincent, Angew. Chem., Int. Ed., 2014, 53, 11881; (c) Y. Xia, Y. M. Xia, R. Ge, Z. Liu, Q. Xiao, Y. Zhang and J. B. Wang, Angew. Chem., Int. Ed., 2014, 53, 3917; (d) J. X. Shen, D. J. Yang, Y. X. Liu, S. S. Qin, J. W. Zhang, J. K. Sun, C. H. Liu, C. Y. Liu, X. M. Zhao, C. H. Chu and R. H. Liu, Org. Lett., 2014, 16, 350; (e) M. N. Zhao, Z. H. Ren, Y. Y. Wang and Z. H. Guan, Org. Lett., 2014, 16, 608; (f) S. Tang, X. D. Wu, W. Q. Liao, K. Liu, C. Liu, S. Z. Luo and A. W. Lei, Org. Lett., 2014, 16, 3584; (g) N. Gigant and J.-E. Bäckvall, Org. Lett., 2014, 16, 1664; (h) Z. G. Zhang and X. F. Jiang, Org. Lett., 2014, 16, 4400; (i) H. H. Peng, Y. M. Xi, N. M. Ronaghi, B. L. Dong, N. G. Akhmedov and X. D. Shi, J. Am. Chem. Soc., 2014, 136, 13174; (j) D. Wang, Y. Izawa and S. S. Stahl, J. Am. Chem. Soc., 2014, 136, 9914.
- 3 (a) T. Nobuta, N. Tada, A. Fujiya, A. Kariya, T. Miura and
 A. Itoh, *Org. Lett.*, 2013, 15, 574; (b) J. Dhineshkumar,
 M. Lamani, K. Alagiri and K. R. Prabhu, *Org. Lett.*, 2013, 15, 1092.
- 4 (a) F. Jia, Y. Zhu, M. Liu, M. Lian, Q. Gao, Q. Cai and A. Wu, *Tetrahedron*, 2013, **69**, 7038; (b) Z. Fei, Y. Zhu, M. Liu, F. Jia and A. Wu, *Tetrahedron Lett.*, 2013, **54**, 1222; (c) Y. Zhu, Z. Fei, M. Liu, F. Jia and A. Wu, *Org. Lett.*, 2013, **15**, 378; (d) Y. Zhu, F. Jia, M. Liu and A. Wu, *Org. Lett.*, 2013, **14**, 4414; (e) Y. Zhu, M. Liu, F. Jia, J. Yuan, Q. Gao, M. Lian and A. Wu, *Org. Lett.*, 2013, **14**, 3392; (f) W. Ge and Y. Wei, *RSC Adv.*, 2013, **3**, 10817; (g) W. Ge, X. Zhu and Y. Wei, *Green Chem.*, 2012, **14**, 2066; (h) Y. Ashikari, A. Shimizu, T. Nokami and J. Yoshida, *J. Am. Chem. Soc.*, 2013, **135**, 16070.
- 5 (a) H. Wang, S. Ren, J. Zhang, W. Zhang and Y. Liu, J. Org. Chem., 2015, 80, 6856; (b) H. Min, T. Palani, K. Park, J. Hwang and S. Lee, J. Org. Chem., 2014, 79, 6279; (c) A. Stergiou, A. Bariotaki, D. Kalaitzakis and I. Smonou, J. Org. Chem., 2013, 78, 7268; (d) B. Schmidt, S. Krehl and S. Hauke, J. Org. Chem., 2013, 78, 5427; (e) A. Wang, H. Jiang and X. Li, J. Org. Chem., 2011, 76, 6958; (f) L. Huang, K. Cheng, B. Yao, Y. Xie and Y. Zhang, J. Org. Chem., 2011, 76, 5732; (g) M. Lian, Q. Li, Y. Zhu, G. Yin and A. Wu, Tetrahedron, 2012, 68, 9598; (h) C. F. Xu, M. Xu, Y. X. Jia and C. Y. Li, Org. Lett., 2011, 13, 1556; (*i*) E. Merkul, J. Dohe, C. Gers, F. Rominger and T. J. Mîller, Angew. Chem., Int. Ed., 2011, 123, 3023; (j) W. X. Lv, Y. F. Zeng, S. S. Zhang, Q. Li and H. Wang, Org. Lett., 2015, 17, 2972; (k) Q. Xing, L. Shi, R. Lang, C. Xia and F. Li, Chem. Commun., 2012, 48, 11023.

- 6 (a) Z. Wan, C. D. Jones, D. Mitchell, J. Y. Pu and T. Y. Zhang, *J. Org. Chem.*, 2006, 71, 826; (b) S. Chen, Z. Liu, E. Shi, L. Chen, W. Wei, H. Li, Y. Cheng and X. Wan, *Org. Lett.*, 2011, 13, 2274.
- 7 (a) J. C. Wu, R. J. Song, Z. Q. Wang, X. C. Huang, Y. X. Xie and J. H. Li, *Angew. Chem., Int. Ed.*, 2012, 51, 3453;
 (b) R. Y. Tang, X. K. Guo, J. Xiang and J. H. Li, *J. Org. Chem.*, 2013, 78, 11163; (c) S. M. A. Shakoor, D. S. Agarwal, A. Kumar and R. Sakhuja, *Tetrahedron*, 2016, 72, 645;
 (d) J. M. Yang, Z. J. Cai, Q. D. Wang, D. Fang and S. J. Ji, *Tetrahedron*, 2015, 71, 7010.
- 8 S. Lei, G. Chen, Y. Mai, L. Chen, H. Cai, J. Tan and H. Cao, *Adv. Synth. Catal.*, 2016, **358**, 67.
- 9 Q. Gao, J. Zhang, X. Wu, S. Liu and A. Wu, Org. Lett., 2015, 17, 134.
- 10 Y. P. Zhu, M. C. Liu, F. C. Jia, J. J. Yuan, Q. H. Gao, M. Lian and A. X. Wu, Org. Lett., 2012, 14, 3392.
- 11 M. Chennapuram, N. Reddy, E. Chiranjeevi, C. Bingi and K. Atmakur, *RSC Adv.*, 2015, **5**, 19418.
- 12 S. Samanta, S. Mondal, S. Santra, G. Kibriya and A. Hajra, *J. Org. Chem.*, 2016, **81**, 10088.
- 13 G. Satish, A. Polu, T. Ramara and A. Ilangovan, *J. Org. Chem.*, 2015, **80**, 5167.
- 14 (a) W.-J. Xue, W. Zhang, K.-L. Zheng, Y. Dai, Y.-Q. Guo, H.-Z. Li, F.-F. Gao and A.-X. Wu, *Asian J. Org. Chem.*, 2013, 2, 638; (b) Y.-P. Zhu, F.-C. Jia, M.-C. Liu and A.-X. Wu, *Org. Lett.*, 2012, 14, 4414.
- V. K. K. Durga Rao, M. Prathap Reddy, P. Sathyanarayana, O. Ravi, R. Kant and B. Surender Reddy, *Chem. Commun.*, 2014, **50**, 13517.
- 16 P. K. Hanuman, S. V. Kamlesh and A. C. Chaskar, *RSC Adv.*, 2014, 4, 60316.
- 17 (a) S. V. Kamlesh, P. K. Hanuman, K. Murugan and A. C. Chaskar, *RSC Adv.*, 2015, 5, 5580; (b) R. Deshidi, M. Kumar, S. Devari and B. A. Shah, *Chem. Commun.*, 2014, 50, 9533; (c) R. Deshidi, S. Devari and B. A. Shah, *Eur. J. Org. Chem.*, 2015, 1428.
- 18 (a) J. Hulten, N. M. Bonham, U. Nillroth, T. Hansson, G. Zuccarello, A. Bouzide, J. Aaqvist, B. Classon and H. Danielson, J. Med. Chem., 1997, 40, 885; (b) S. P. Shaik, V. L. Nayak, F. Sultana, A. V. S. Rao, A. B. Shaik, K. S. Babu and A. Kamal, Eur. J. Med. Chem., 2017, 126, 36; (c) A. R. Katritzky, J. Wu, S. Rachwal, B. Rachwal, D. W. Macomber and T. P. Smith, Org. Prep. Proced., 1992, 24, 463; (d) I. R. Greig, M. J. Tozer and P. T. Wright, Org. Lett., 2001, 3, 369; (e) D. M. Matthew, M. D. Joseph and R. H. Paul, Chem. Rev., 2004, 104, 2239; (f) S. P. Shaik, M. V. P. S. Vishnuvardhan, F. Sultana, A. V. S. Rao, C. Bagul, D. Bhattacharjee, J. S. Kapure, N. Jain and A. Kamal, Bioorg. Med. Chem., 2017, 25, 3285.
- 19 M. Palkar, M. Noolvi, R. Sankangoud, V. Maddi, A. Gadad and L. V. Nargund, *Arch. Pharm.*, 2010, **343**, 353.
- 20 T. H. Al-Tel, R. A. Al-Qawasmeh and R. Zaarour, *Eur. J. Med. Chem.*, 2011, **46**, 1874.

- 21 J. K. Malik, H. Soni and A. K. Singhai, *J. Pharm. Res.*, 2013, 7, 39.
- 22 T. Mase, H. Arima, K. Tomioka, T. Yamada and K. Murase, *J. Med. Chem.*, 1986, **29**, 386.
- 23 I. R. Ager, A. C. Barnes, G. W. Danswan, P. W. Hairsine, D. P. Kay, P. D. Kennewell, S. S. Matharu, P. Miller, P. Robson and D. A. Rowlands, *J. Med. Chem.*, 1988, 31, 1098.
- 24 S. Clements-Jewery, G. Danswan, C. R. Gardner,
 S. S. Matharu, R. Murdoch, W. R. Tully and R. Westwood, *J. Med. Chem.*, 1988, 31, 1220.
- (a) K. Srimanth, V. R. Rao and D. R. Krishna, Arzneim. Forsch., 2002, 52, 388; (b) G. Trapani, M. Franco, A. Latrofa, A. Reho and G. Liso, Eur. J. Pharm. Sci., 2001, 14, 209; (c) N. Aminoa, Y. Ideyamaa, M. Yamanoa, S. Kuromitsub, K. Tajindab, K. Samizuc, A. Matsuhisad, M. Kudoha and M. Shibasaki, Cancer Lett., 2006, 238, 119.
- 26 Q. Chao, K. G. Sprankle, K. M. Grotzfeld, A. G. Lai, T. A. Carter, A. M. Velasco, R. N. Gunawardane, M. D. Cramer, M. F. Gardner, J. James, P. P. Zarrinkar, H. K. Patel and S. S. Bhagwat, *J. Med. Chem.*, 2009, 52, 7808.
- 27 (a) C. Blackburn, M. O. Duffey, A. E. Gould and B. Kulkarni, *Bioorg. Med. Chem. Lett.*, 2010, 20, 4795;
 (b) A. Andreani, M. Granaiola, A. Leoni, A. Locatelli and R. Morigi, *Eur. J. Med. Chem.*, 2011, 46, 4311;
 (c) B. H. Yousefi, A. Manook, A. Drzezga and B. Reutern, *J. Med. Chem.*, 2011, 54, 949; (d) D. Alagille, H. DaCosta, R. M. Baldwin and G. D. Tamagnan, *Bioorg. Med. Chem. Lett.*, 2011, 21, 2966; (e) B. H. Yousefi, A. Drzezga, B. Reutern and A. Manook, *Med. Chem. Lett.*, 2011, 2, 673.
- 28 A. Kamal, F. Sultana, M. Janaki Ramaiah, Y. V. V. Srikanth, A. Viswanath, C. Kishor, P. Sharma, S. N. C. V. L. Pushpavalli, A. Addlagatta and M. P. Bhadra, *ChemMedChem*, 2012, 7, 292.
- 29 F. Sultana, S. P. Shaik, A. Alarifi, A. K. Srivastava and A. Kamal, *Asian J. Org. Chem.*, 2017, **6**, 890.
- 30 F.-C. Jia, Y.-P. Zhu, M.-C. Liu, M. Lian, Q.-H. Gao, Q. Cai and A.-X. Wu, *Tetrahedron*, 2013, **69**, 7038.
- 31 (a) H. Jiang, H. Huang, H. Cao and C. Qi, Org. Lett., 2010,
 12, 5561; (b) K. K. Viswanadham, R. M. Prathap,
 P. Sathyanarayana, O. Ravi, R. Kant and S. R. Bathula, Chem. Commun., 2014, 50, 13517; (c) H. P. Kalmode,
 K. S. Vadagaonkar and A. C. Chaskar, RSC Adv., 2014, 4, 60316.
- 32 S. Liu, H. Xi, J. Zhang, X. Wu, Q. Gao and A. Wu, Org. Biomol. Chem., 2015, 13, 8807.
- 33 (a) A. K. Bagdi, M. Rahman, S. Santra, A. Majee and
 A. Hajra, *Adv. Synth. Catal.*, 2013, 355, 1741; (b) S. Mishra,
 K. Monir, S. Mitra and A. Hajra, *Org. Lett.*, 2014, 16, 6084.
- 34 A. K. Pandey, R. Sharma, A. Singh, S. Shukla, K. Srivastava,
 S. K. Puri, B. Kumar and P. M. S. Chauhan, *RSC Adv.*, 2014,
 4, 26757.
- 35 X.-S. Fan, J. Zhang, B. Li and X.-Y. Zhang, *Chem. Asian J.*, 2015, **10**, 1281.